BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 15289074)

  • 1. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
    Urlacher VB; Schmid RD
    Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
    [No Abstract]   [Full Text] [Related]  

  • 2. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3.
    Peters MW; Meinhold P; Glieder A; Arnold FH
    J Am Chem Soc; 2003 Nov; 125(44):13442-50. PubMed ID: 14583039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
    Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
    Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obligatory intermolecular electron-transfer from FAD to FMN in dimeric P450BM-3.
    Kitazume T; Haines DC; Estabrook RW; Chen B; Peterson JA
    Biochemistry; 2007 Oct; 46(42):11892-901. PubMed ID: 17902705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
    Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
    Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory evolution of cytochrome p450 BM-3 monooxygenase for organic cosolvents.
    Wong TS; Arnold FH; Schwaneberg U
    Biotechnol Bioeng; 2004 Feb; 85(3):351-8. PubMed ID: 14748091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.
    Oliver CF; Modi S; Sutcliffe MJ; Primrose WU; Lian LY; Roberts GC
    Biochemistry; 1997 Feb; 36(7):1567-72. PubMed ID: 9048540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
    Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
    Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties.
    Fasan R; Chen MM; Crook NC; Arnold FH
    Angew Chem Int Ed Engl; 2007; 46(44):8414-8. PubMed ID: 17886313
    [No Abstract]   [Full Text] [Related]  

  • 11. Protein-binding DNA regions inside and in the vicinity of the cytochrome P450bm-3 gene from Bacillus megaterium.
    Gaidamakova EK; Karginov VA; Kovalenko SP
    Biochem Biophys Res Commun; 1994 Feb; 198(3):862-8. PubMed ID: 8117290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450.
    Otey CR; Bandara G; Lalonde J; Takahashi K; Arnold FH
    Biotechnol Bioeng; 2006 Feb; 93(3):494-9. PubMed ID: 16224788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A.
    Schwaneberg U; Schmidt-Dannert C; Schmitt J; Schmid RD
    Anal Biochem; 1999 May; 269(2):359-66. PubMed ID: 10222011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress towards the easier use of P450 enzymes.
    Chefson A; Auclair K
    Mol Biosyst; 2006 Oct; 2(10):462-9. PubMed ID: 17216026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of kinetic isotope effects to delineate the role of phenylalanine 87 in P450(BM-3).
    Rock DA; Boitano AE; Wahlstrom JL; Rock DA; Jones JP
    Bioorg Chem; 2002 Apr; 30(2):107-18. PubMed ID: 12020135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screens based on NAD(P)H depletion.
    Glieder A; Meinhold P
    Methods Mol Biol; 2003; 230():157-70. PubMed ID: 12824579
    [No Abstract]   [Full Text] [Related]  

  • 17. Are branched chain fatty acids the natural substrates for P450(BM3)?
    Cryle MJ; Espinoza RD; Smith SJ; Matovic NJ; De Voss JJ
    Chem Commun (Camb); 2006 Jun; (22):2353-5. PubMed ID: 16733577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional saturation mutagenesis as an approach to identification of substrate specificity determinants in cytochrome P450 BM3.
    Munro AW; Coggins JR; Lindsay JG
    Biochem Soc Trans; 1993 Nov; 21(4):409S. PubMed ID: 8131983
    [No Abstract]   [Full Text] [Related]  

  • 19. Toward understanding the inactivation mechanism of monooxygenase P450 BM-3 by organic cosolvents: a molecular dynamics simulation study.
    Roccatano D; Wong TS; Schwaneberg U; Zacharias M
    Biopolymers; 2006 Dec; 83(5):467-76. PubMed ID: 16862534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
    Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U
    Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.